MRK ▼ -0.3% - Merck & Co., Inc.
$MRK - European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
21-OCT-2026 06:54 AM ET
Share this post
More filings for $MRK
MRK ▼ -0.3% - Merck & Co., Inc.Oct 21, 2026MRK ▼ -0.4% - Merck & Co., Inc.Oct 13, 2026MRK ▲ +2.8% - Merck & Co., Inc.Oct 10, 2026MRK ▲ +0.1% - Merck & Co., Inc.Sep 28, 2026MRK ▲ +0.4% - Merck & Co., Inc.Sep 25, 2026MRK ▲ +0.2% - Merck & Co., Inc.Sep 22, 2026
View full $MRK filing history →💬 Comments
Loading comments…
Leave a comment